1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 75, 2024
  5. Article

Annual Review of Medicine

Volume 75, 2024

Novel Therapeutic and Program-Based Approaches to Opioid Use Disorders

Abstract

Opioid use disorder continues to drive overdose deaths in many countries, including the United States. Illicit fentanyl and its analogues have emerged as key contributors to the complications and mortality associated with opioid use disorder. Medications for opioid use disorder treatment, such as methadone and buprenorphine, are safe and substantially reduce opioid use, infectious complications, and mortality risk, but remain underutilized. Polysubstance use and emerging substances such as xylazine and designer benzodiazepines create additional treatment challenges. Recent clinical and policy innovations in treatment delivery, including telemedicine, bridge clinics, and expanded models for accessing methadone have the potential to increase access to life-saving care for people living with opioid use disorder.

Keyword(s): buprenorphine, harm reduction, injection drug use, methadone, opioid-related disorders, telemedicine
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050522-033924
2024-01-29
2024-05-06
Loading full text...

Full text loading...

/deliver/fulltext/med/75/1/annurev-med-050522-033924.html?itemId=/content/journals/10.1146/annurev-med-050522-033924&mimeType=html&fmt=ahah

Literature Cited

  1. 1.
    Natl. Cent. Health Stat 2022. Life expectancy in the U.S. dropped for the second year in a row in 2021 News Release, Aug. 31 CDC Natl. Cent. Health Stat. Hyattsville, MD: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220831.htm .
  2. 2.
    Natl. Cent. Health Stat 2023. 2022 Drug overdose deaths https://www.cdc.gov/nchs/hus/topics/drug-overdose-deaths.htm. Updated June 26, 2023
  3. 3.
    Ahmad FB, Rossen LM, Sutton P. 2023. Provisional drug overdose death counts Natl. Cent. Health Stat. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed Jan. 10, 2023
  4. 4.
    Wakeman SE, Larochelle MR, Ameli O et al. 2020. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw. Open 3:e1920622
     [Google Scholar]
  5. 5.
    Sordo L, Barrio G, Bravo MJ et al. 2017. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 357:j1550
     [Google Scholar]
  6. 6.
    Dole VP, Nyswander M. 1965. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193:646–50
     [Google Scholar]
  7. 7.
    Nilsson MI, Meresaar U, Anggård E. 1982. Clinical pharmacokinetics of methadone. Acta Anaesthesiol. Scand. Suppl. 74:66–69
     [Google Scholar]
  8. 8.
    Jaffe JH, O'Keeffe C. 2003. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 70:S3–11
     [Google Scholar]
  9. 9.
    Marsch LA. 1998. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 93:515–32
     [Google Scholar]
  10. 10.
    Mattick RP, Breen C, Kimber J, Davoli M. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009:CD002209
     [Google Scholar]
  11. 11.
    Elkader A, Sproule B. 2005. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 44:661–80
     [Google Scholar]
  12. 12.
    FDA 2002. Drug approval package—subutex (buprenorphine HCl) suboxone (buprenorphine HCl & naloxone HCl dihydrate) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-732_20-733_subutex.cfm
  13. 13.
    Lexicomp 2023. Buprenorphine: drug information. https://online.lexi.com/lco/medguides/652590.pdf
  14. 14.
    FDA 2023. FDA approves new buprenorphine treatment option for opioid use disorder News Release, May 23 US Food Drug Adm. Silver Spring, MD: https://www.fda.gov/news-events/press-announcements/fda-approves-new-buprenorphine-treatment-option-opioid-use-disorder
  15. 15.
    Mattick RP, Breen C, Kimber J, Davoli M. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2014:CD002207
     [Google Scholar]
  16. 16.
    Rosado J, Walsh SL, Bigelow GE, Strain EC. 2007. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend. 90:261–69
     [Google Scholar]
  17. 17.
    Edinoff AN, Fahmy OH, Spillers NJ et al. 2023. Low-dose initiation of buprenorphine: a narrative review. Curr. Pain Headache Rep. 27:175–81
     [Google Scholar]
  18. 18.
    Volkow ND. 2021. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry 20:195–96
     [Google Scholar]
  19. 19.
    Herring AA, Vosooghi AA, Luftig J et al. 2021. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Netw. Open 4:e2117128
     [Google Scholar]
  20. 20.
    Randall A, Hull I, Martin SA. 2023. Enhancing patient choice: using self-administered intranasal naloxone for novel rapid buprenorphine initiation. J. Addict. Med. 17:237–40
     [Google Scholar]
  21. 21.
    Bigelow GE, Preston KL, Schmittner J et al. 2012. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend. 123:57–65
     [Google Scholar]
  22. 22.
    Minozzi S, Amato L, Vecchi S et al. 2011. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 2011:CD001333
     [Google Scholar]
  23. 23.
    Syed YY, Keating GM. 2013. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs 27:851–61
     [Google Scholar]
  24. 24.
    Krupitsky E, Nunes EV, Ling W et al. 2011. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377:1506–13
     [Google Scholar]
  25. 25.
    Lee JD, Nunes EV Jr., Novo P et al. 2018. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391:309–18
     [Google Scholar]
  26. 26.
    Korthuis PT, Cook RR, Lum PJ et al. 2022. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. Addiction 117:1961–71
     [Google Scholar]
  27. 27.
    Haeny AM, Montgomery L, Burlew AK et al. 2020. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. Addict. Behav. 110:106514
     [Google Scholar]
  28. 28.
    Jarvis BP, Holtyn AF, Subramaniam S et al. 2018. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction 113:1188–209
     [Google Scholar]
  29. 29.
    Bisaga A, Mannelli P, Yu M et al. 2018. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial. Drug Alcohol Depend. 187:171–78
     [Google Scholar]
  30. 30.
    Lee JD, Friedmann PD, Kinlock TW et al. 2016. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N. Engl. J. Med. 374:1232–42
     [Google Scholar]
  31. 31.
    McCarty D, Priest KC, Korthuis PT. 2018. Treatment and prevention of opioid use disorder: challenges and opportunities. Annu. Rev. Public Health 39:525–41
     [Google Scholar]
  32. 32.
    Fiellin DA, Pantalon MV, Chawarski MC et al. 2006. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N. Engl. J. Med. 355:365–74
     [Google Scholar]
  33. 33.
    Weiss RD, Potter JS, Fiellin DA et al. 2011. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 68:1238–46
     [Google Scholar]
  34. 34.
    Humphreys K, Barreto NB, Alessi SM et al. 2020. Impact of 12 step mutual help groups on drug use disorder patients across six clinical trials. Drug Alcohol Depend. 215:108213
     [Google Scholar]
  35. 35.
    Bassuk EL, Hanson J, Greene RN et al. 2016. Peer-delivered recovery support services for addictions in the United States: a systematic review. J. Subst. Abuse Treat. 63:1–9
     [Google Scholar]
  36. 36.
    Stack E, Hildebran C, Leichtling G et al. 2021. Peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings—a narrative review. J. Addict. Med. 16:93–100
     [Google Scholar]
  37. 37.
    Davidson L, Bellamy C, Guy K, Miller R. 2012. Peer support among persons with severe mental illnesses: a review of evidence and experience. World Psychiatry 11:123–28
     [Google Scholar]
  38. 38.
    Collins D, Alla J, Nicolaidis C et al. 2019.. “ If it wasn't for him, I wouldn't have talked to them”: qualitative study of addiction peer mentorship in the hospital. J. Gen. Intern. Med. https://doi.org/10.1007/s11606-019-05311-0
    [Google Scholar]
  39. 39.
    Schuler MS, Saloner B, Gordon AJ et al. 2023. National trends in buprenorphine treatment for opioid use disorder from 2007 to 2018. Subst. Abuse. https://doi.org/10.1177/08897077231179576
    [Google Scholar]
  40. 40.
    Krawczyk N, Rivera BD, Jent V et al. 2022. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. Int. J. Drug Policy 110:103786
     [Google Scholar]
  41. 41.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2023. Waiver elimination (MAT Act) https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act
  42. 42.
    Roy PJ, Choi S, Bernstein E, Walley AY. 2020. Appointment wait-times and arrival for patients at low-barrier access addiction clinic. J. Subst. Abuse Treat. 114:108011
     [Google Scholar]
  43. 43.
    Modesto-Lowe V, Jain L 2023. Buprenorphine maintenance in the fentanyl era: challenges and opportunities. Prim. Care Companion CNS Disord. 25:22cr03463
     [Google Scholar]
  44. 44.
    Wakeman SE, Chang Y, Regan S et al. 2019. Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence. J. Addict. Med. 13:253–57
     [Google Scholar]
  45. 45.
    Danilewitz M, McLean M. 2020. High-dose buprenorphine for treatment of high potency opioid use disorder. Drug Alcohol Rev. 39:135–37
     [Google Scholar]
  46. 46.
    Taylor JL, Wakeman SE, Walley AY, Kehoe LG. 2023. Substance use disorder bridge clinics: models, evidence, and future directions. Addict. Sci. Clin. Pract. 18:23
     [Google Scholar]
  47. 47.
    Drug Enforc. Adm. (DEA) 2009. Implementation of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Interim final rule with request for comments. Fed. Regist. 74:15595–625
     [Google Scholar]
  48. 48.
    Drug Enforc. Adm. (DEA) 2020. How to prescribe controlled substances to patients during the COVID-19 public health emergency Guidance document, Diversion Control Div., Drug Enforc. Adm. https://pharmacy.iowa.gov/sites/default/files/dea_prescribing_decision_tree.pdf
  49. 49.
    Drug Enforc. Adm. (DEA) 2023. Temporary extension of COVID–19 telemedicine flexibilities for prescription of controlled medications. Fed. Regist. 88:30037–43
     [Google Scholar]
  50. 50.
    Lockard R, Priest KC, Gregg J, Buchheit BM. 2022. A qualitative study of patient experiences with telemedicine opioid use disorder treatment during COVID-19. Subst. Abuse 43:1150–57
     [Google Scholar]
  51. 51.
    Jones CM, Shoff C, Hodges K et al. 2022. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry 79:981–92
     [Google Scholar]
  52. 52.
    Samuels EA, Khatri UG, Snyder H et al. 2022. Buprenorphine telehealth treatment initiation and follow-up during COVID-19. J. Gen. Intern. Med. 37:1331–33
     [Google Scholar]
  53. 53.
    Brunet N, Moore DT, Lendvai Wischik D et al. 2022. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst. Abuse 43:39–46
     [Google Scholar]
  54. 54.
    Levander XA, Wheelock H, Pope J et al. 2022. Low-threshold buprenorphine via community partnerships and telemedicine—case reports of expanding access to addiction treatment during COVID-19. J. Addict. Med. 16:e56–58
     [Google Scholar]
  55. 55.
    Inst. Med. Comm. Fed. Regul. Methadone Treatment 1995. Introduction. Federal Regulation of Methadone Treatment RA Rettig, A Yarmolinsky Washington, DC: Natl. Acad. Press https://www.ncbi.nlm.nih.gov/books/NBK232114/
    [Google Scholar]
  56. 56.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2015. Federal guidelines for opioid treatment programs HHS Publ. No. (SMA) PEP15-FEDGUIDEOTP Subst. Abuse Mental Health Serv. Adm. Rockville, MD:
  57. 57.
    Jackson JR, Harle CA, Silverman RD et al. 2020. Characterizing variability in state-level regulations governing opioid treatment programs. J. Subst. Abuse Treat. 115:108008
     [Google Scholar]
  58. 58.
    Peles E, Schreiber S, Sason A, Adelson M. 2011. Earning “take-home” privileges and long-term outcome in a methadone maintenance treatment program. J. Addict. Med. 5:92–98
     [Google Scholar]
  59. 59.
    Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. 2019. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw. Open 2:e196373
     [Google Scholar]
  60. 60.
    Lister JJ, Weaver A, Ellis JD et al. 2020. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am. J. Drug Alcohol Abuse 46:273–88
     [Google Scholar]
  61. 61.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2020. Opioid Treatment Program (OTP) guidance Subst. Abuse Mental Health Serv. Adm. Rockville, MD: https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf
  62. 62.
    Jones CM, Compton WM, Han B et al. 2022. Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiatry 79:932–34
     [Google Scholar]
  63. 63.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2022. Medications for the treatment of opioid use disorder. Fed. Regist. 87:77330–65
     [Google Scholar]
  64. 64.
    Chan B, Hoffman KA, Bougatsos C et al. 2021. Mobile methadone medication units: a brief history, scoping review and research opportunity. J. Subst. Abuse Treat. 129:108483
     [Google Scholar]
  65. 65.
    Drug Enforc. Adm. (DEA) 2021. Registration requirements for narcotic treatment programs with mobile components. Fed. Regist. 86:33861–33885
     [Google Scholar]
  66. 66.
    Greenfield L, Brady JV, Besteman KJ, De Smet A. 1996. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 42:125–31
     [Google Scholar]
  67. 67.
    Hall G, Neighbors CJ, Iheoma J et al. 2014. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J. Subst. Abuse Treat. 46:511–15
     [Google Scholar]
  68. 68.
    FDA 2023. 21CFR1306.07. 21—Administering or dispending of narcotic drugs. Code Fed. Regul. Title 21 , Vol. 9 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=1306.07
  69. 69.
    Taylor JL, Laks J, Christine PJ et al. 2022. Bridge clinic implementation of “72-hour rule” methadone for opioid withdrawal management: impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 236:109497
     [Google Scholar]
  70. 70.
    Huo S, Heil J, Salzman MS et al. 2023. Methadone initiation in the emergency department for opioid use disorder: a case series. J. Emerg. Med. 64:391–96
     [Google Scholar]
  71. 71.
    Chan B, Bougatsos C, Priest KC et al. 2022. Opioid treatment programs, telemedicine and COVID-19: a scoping review. Subst. Abuse 43:539–46
     [Google Scholar]
  72. 72.
    King VL, Brooner RK, Peirce JM et al. 2014. A randomized trial of Web-based videoconferencing for substance abuse counseling. J. Subst. Abuse Treat. 46:36–42
     [Google Scholar]
  73. 73.
    Eibl JK, Gauthier G, Pellegrini D et al. 2017. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend. 176:133–38
     [Google Scholar]
  74. 74.
    Hallgren KA, Darnton J, Soth S et al. 2022. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic. J. Subst. Abuse Treat. 143:108896
     [Google Scholar]
  75. 75.
    Darnton JB, Bhatraju EP, Beima-Sofie K et al. 2023.. “ Sign me up”: a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic. Addict. Sci. Clin. Pract. 18:21
     [Google Scholar]
  76. 76.
    Dunn KE, Brooner RK, Stoller KB. 2021. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. J. Subst. Abuse Treat. 121:108197
     [Google Scholar]
  77. 77.
    Calcaterra SL, Bach P, Chadi A et al. 2019. Methadone matters: what the United States can learn from the global effort to treat opioid addiction. J. Gen. Intern. Med. 34:1039–42
     [Google Scholar]
  78. 78.
    Fiellin DA. 2023. Office-based methadone versus buprenorphine to address retention in medication for opioid use disorder (MOUD)–a pragmatic hybrid effectiveness/implementation trial CTN-0131 Natl. Drug Abuse Treat. Clin. Trials Dissemin. Libr. https://ctnlibrary.org/protocol/ctn0131-2/
  79. 79.
    Fiellin DA, O'Connor PG, Chawarski M et al. 2001. Methadone maintenance in primary care: a randomized controlled trial. JAMA 286:1724–31
     [Google Scholar]
  80. 80.
    King VL, Kidorf MS, Stoller KB et al. 2006. A 12-month controlled trial of methadone medical maintenance integrated into an adaptive treatment model. J. Subst. Abuse Treat. 31:385–93
     [Google Scholar]
  81. 81.
    Tuchman E, Gregory C, Simson M, Drucker E. 2006. Safety, efficacy, and feasibility of office-based prescribing and community pharmacy dispensing of methadone: results of a pilot study in New Mexico. Addict. Disord. Treat. 5:43–51
     [Google Scholar]
  82. 82.
    Drucker E, Rice S, Ganse G et al. 2007. The Lancaster office based opiate treatment program: a case study and prototype for community physicians and pharmacists providing methadone maintenance treatment in the United States. Addict. Disord. Treat. 6:121–35
     [Google Scholar]
  83. 83.
    Harris KA Jr., Arnsten JH, Joseph H et al. 2006. A 5-year evaluation of a methadone medical maintenance program. J. Subst. Abuse Treat. 31:433–38
     [Google Scholar]
  84. 84.
    Kleinman RA. 2020. Comparison of driving times to opioid treatment programs and pharmacies in the US. JAMA Psychiatry 77:1163–71
     [Google Scholar]
  85. 85.
    Walley AY, Xuan Z, Hackman HH et al. 2013. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 346:f174
     [Google Scholar]
  86. 86.
    Jakubowski A, Fowler S, Fox AD. 2023. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. Addict. Sci. Clin. Pract. 18:40
     [Google Scholar]
  87. 87.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2022. Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health Rep., SAMHSA, US Dep. Health Hum. Serv., HHS Publ. No. PEP22-07-01-005, NSDUH Ser. H-57
  88. 88.
    Friedman JR, Hansen H. 2022. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic. JAMA Psychiatry 79:379–81
     [Google Scholar]
  89. 89.
    Kariisa M, Davis NL, Kumar S et al. 2022. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics—25 states and the District of Columbia, 2019–2020. Morb. Mortal. Wkly. Rep. 71:940–47
     [Google Scholar]
  90. 90.
    Goedel WC, Shapiro A, Cerda M et al. 2020. Association of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw. Open 3:e203711
     [Google Scholar]
  91. 91.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2023. 2021 National Survey on Drug Use and Health (NSDUH) releases NSDUH-2021-DS0001. https://www.samhsa.gov/data/release/2021-national-survey-drug-use-and-health-nsduh-releases
  92. 92.
    Cicero TJ, Ellis MS, Kasper ZA. 2020. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am. J. Public Health 110:244–50
     [Google Scholar]
  93. 93.
    Subst. Abuse Mental Health Serv. Adm. (SAMHSA) 2019. 2017 National Survey on Drug Use and Health (NSDUH) releases NSDUH-2017-DS0001. https://www.samhsa.gov/data/release/2017-national-survey-drug-use-and-health-nsduh-releases
  94. 94.
    King C, Nicolaidis C, Korthuis PT et al. 2020. Patterns of substance use before and after hospitalization among patients seen by an inpatient addiction consult service: a latent transition analysis. J. Subst. Abuse Treat. 118:108121
     [Google Scholar]
  95. 95.
    Barocas JA, Wang J, Marshall BDL et al. 2019. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 200:59–63
     [Google Scholar]
  96. 96.
    Barenholtz E, Krotulski AJ, Morris P et al. 2021. Online surveillance of novel psychoactive substances (NPS): monitoring Reddit discussions as a predictor of increased NPS-related exposures. Int. J. Drug Policy 98:103393
     [Google Scholar]
  97. 97.
    Holt AC, Schwope DM, Le K et al. 2023. Widespread distribution of xylazine detected throughout the United States in healthcare patient samples. J. Addict. Med. 17:468–70
     [Google Scholar]
  98. 98.
    Johnson J, Pizzicato L, Johnson C, Viner K. 2021. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010–2019. Inj. Prev. 27:395–98
     [Google Scholar]
  99. 99.
    Friedman J, Montero F, Bourgois P et al. 2022. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 233:109380
     [Google Scholar]
/content/journals/10.1146/annurev-med-050522-033924
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error